Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as Nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL). Several studies have shown convincing therapeutic effects of Nivolumab in cH...

Descripción completa

Detalles Bibliográficos

Autores principales:	Kübra Yadigaroglu, Sonja Scharf, Steffen Gretser, Hendrik Schäfer, Aresu Sadeghi Shoreh Deli, Andreas G. Loth, Hasmik Yegoryan, Roland Schmitz, Emmanuel Donnadieu, Martin-Leo Hansmann, Sylvia Hartmann
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Ferrata Storti Foundation 2024-05-01
Colección:	Haematologica
Acceso en línea:	https://haematologica.org/article/view/11608
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!